CN111278862A - 用于治疗成神经细胞瘤的抗gd2抗体 - Google Patents

用于治疗成神经细胞瘤的抗gd2抗体 Download PDF

Info

Publication number
CN111278862A
CN111278862A CN201880065543.8A CN201880065543A CN111278862A CN 111278862 A CN111278862 A CN 111278862A CN 201880065543 A CN201880065543 A CN 201880065543A CN 111278862 A CN111278862 A CN 111278862A
Authority
CN
China
Prior art keywords
antibody
fragment
iga
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880065543.8A
Other languages
English (en)
Chinese (zh)
Inventor
珍妮特·亨利查·威廉明娜·勒森
约翰尼斯·赫拉尔杜斯·玛丽亚·埃弗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TigaTx Inc
Original Assignee
UMC Utrecht Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UMC Utrecht Holding BV filed Critical UMC Utrecht Holding BV
Publication of CN111278862A publication Critical patent/CN111278862A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201880065543.8A 2017-09-21 2018-09-21 用于治疗成神经细胞瘤的抗gd2抗体 Pending CN111278862A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17192476.4 2017-09-21
EP17192476 2017-09-21
PCT/NL2018/050629 WO2019059771A2 (en) 2017-09-21 2018-09-21 ANTI-GD2 ANTIBODIES FOR THE TREATMENT OF NEUROBLASTOMA

Publications (1)

Publication Number Publication Date
CN111278862A true CN111278862A (zh) 2020-06-12

Family

ID=59955406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880065543.8A Pending CN111278862A (zh) 2017-09-21 2018-09-21 用于治疗成神经细胞瘤的抗gd2抗体

Country Status (12)

Country Link
US (2) US11866511B2 (https=)
EP (1) EP3684818A2 (https=)
JP (2) JP2020534370A (https=)
KR (1) KR20200059249A (https=)
CN (1) CN111278862A (https=)
AU (3) AU2018336017B2 (https=)
BR (1) BR112020005742A2 (https=)
CA (1) CA3076482A1 (https=)
IL (1) IL273454A (https=)
MX (1) MX2020003201A (https=)
SG (1) SG11202002581WA (https=)
WO (1) WO2019059771A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096559B (zh) * 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
CN111849904B (zh) * 2020-07-31 2021-05-04 浙江科途医学科技有限公司 神经母细胞瘤类器官的培养基、培养方法及移植体
EP4326292A4 (en) * 2021-04-23 2025-03-26 Vivasor, Inc. Dimeric antigen receptors (dars) that bind gd2
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049643A2 (en) * 2006-10-27 2008-05-02 Charite - Universitätsmedizin Berlin Gd2 peptide mimotopes for anticancer vaccination
CN105732814A (zh) * 2016-03-08 2016-07-06 苏州大学 抗人血管性血友病因子a3区的人鼠嵌合单克隆抗体及其制备方法和应用
CN106414494A (zh) * 2013-11-12 2017-02-15 Ogd2药物 具有促凋亡活性的人IgG1衍生的抗体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284536B1 (en) 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
US8313730B2 (en) 2006-12-13 2012-11-20 Michael R. Simon Treatment of celiac disease with IgA
EP2578681B1 (en) 2010-05-24 2015-07-01 Kagoshima University Iga-binding peptide and iga purification using same
EP2465536A1 (en) 2010-12-14 2012-06-20 CSL Behring AG CD89 activation in therapy
EP2791170A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
BR112014022240A2 (pt) 2012-03-09 2017-08-01 Csl Behring Ag composições compreendendo imunoglobulinas semelhantes à secretoras
WO2013189516A1 (en) * 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9890216B2 (en) 2012-10-23 2018-02-13 Board Of Regents, The University Of Texas System Antibodies with engineered IgG Fc domains
ES2768649T3 (es) * 2013-11-21 2020-06-23 Apeiron Biologics Ag Preparaciones para tratar un cáncer positivo para GD2
EP3747438A1 (en) 2017-07-24 2020-12-09 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049643A2 (en) * 2006-10-27 2008-05-02 Charite - Universitätsmedizin Berlin Gd2 peptide mimotopes for anticancer vaccination
CN106414494A (zh) * 2013-11-12 2017-02-15 Ogd2药物 具有促凋亡活性的人IgG1衍生的抗体
CN105732814A (zh) * 2016-03-08 2016-07-06 苏州大学 抗人血管性血友病因子a3区的人鼠嵌合单克隆抗体及其制备方法和应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LINDA S. SORKIN等: "Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia" *
LORENZO GALLUZZI等: "Trial Watch: Monoclonal antibodies in cancer therapy" *
RANDALL J BREZSKI等: "Immunoglobulin isotype knowledge and application to Fc engineering" *
SASKIA MEYER等: "Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting" *

Also Published As

Publication number Publication date
AU2018336017B2 (en) 2021-06-24
US20210179732A1 (en) 2021-06-17
KR20200059249A (ko) 2020-05-28
BR112020005742A2 (pt) 2020-10-13
US20200283541A1 (en) 2020-09-10
JP2020534370A (ja) 2020-11-26
AU2025201363A1 (en) 2025-03-20
EP3684818A2 (en) 2020-07-29
SG11202002581WA (en) 2020-04-29
MX2020003201A (es) 2020-08-13
AU2021236513A1 (en) 2021-10-21
CA3076482A1 (en) 2019-03-28
JP2024023238A (ja) 2024-02-21
WO2019059771A3 (en) 2019-10-10
US11866511B2 (en) 2024-01-09
NZ762835A (en) 2024-12-20
IL273454A (en) 2020-05-31
WO2019059771A2 (en) 2019-03-28
AU2018336017A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
US11866511B2 (en) Anti-GD2 antibody
JP7273904B2 (ja) 液性免疫応答の増強方法
TWI906278B (zh) 經遮蔽之il-12細胞激素及其裂解產物
US20250250347A1 (en) Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
JP2021525082A (ja) 抗ｓｉｒｐａ抗体およびその使用法
KR20230142658A (ko) 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
KR20160126027A (ko) 급성 림프아구성 백혈병을 치료하기 위한 항-cd38 항체
KR20170054442A (ko) 항-cd38 항체를 사용하는 병용 요법
JP2018502834A (ja) 急性骨髄性白血病の治療のための抗ｃｄ３８抗体
US20230235055A1 (en) Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
CN113906052A (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
TR201816437T4 (tr) Azalmış ve artmış efektör fonksiyonuna sahip olacak şekilde tasarlanmış iki antikor içeren bileşim.
JP2021513329A (ja) 抗ｍｓ４ａ４ａ抗体及びその使用方法
JP2022538718A (ja) 二重特異性抗体及びその調製方法、使用
JP7490923B2 (ja) 免疫療法効果が向上し副作用が軽減した変異抗ｃｔｌａ－４抗体
JPWO2020004492A1 (ja) Ｃｅｌｌ Ａｄｈｅｓｉｏｎ Ｍｏｌｅｃｕｌｅ３に結合する抗体
KR20220070201A (ko) 항-pd-1 항체 및 이의 용도
US20230022731A1 (en) Engineered antibodies and methods of treatment
JPWO2020004490A1 (ja) コンドロイチン硫酸プロテオグリカン−５に結合する抗体
Vankemmelbeke et al. Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan–Targeting Antibodies without the Need for Immune Effector Cells or Complement
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
WO2023116770A1 (zh) 针对FcγRIIA的结合分子及其应用
Puri The Evaluation of MS4A4A and MS4A8B Expression in Hematopoietic Cells
KR102955590B1 (ko) 인간화 항-SIRPα 항체
TW202509067A (zh) 抗ｃｄ２５抗體及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Janet Henrika William Minna Larsen

Inventor after: Johannes heraldus Maria Evers

Inventor before: Janet Henrich Wilhelmina Larsen

Inventor before: Johannes heraldus Maria Evers

CB03 Change of inventor or designer information
TA01 Transfer of patent application right

Effective date of registration: 20220429

Address after: Rhodes Island, USA

Applicant after: Tigartx

Address before: Utrecht

Applicant before: UMC UTRECHT HOLDING B.V.

TA01 Transfer of patent application right